For the year ending 2025-12-31, TLSI made $45,151K in revenue. -$69,690K in net income. Net profit margin of -154.35%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 45,151 | |||
| Cost of goods sold | 6,965 | |||
| Gross profit | 38,186 | |||
| Research and development | 14,965 | |||
| Sales and marketing | 28,709 | |||
| General and administrative | 21,458 | |||
| Loss from operations | -26,946 | |||
| Interest income | 555 | |||
| Interest expense | 5,544 | |||
| Change in fair value of sepa, warrant and revenue base redemption liabilities | -4,086 | |||
| Change in fair value of contingent earnout liability | 2,743 | |||
| Other expense, net | -456 | |||
| Loss before income taxes | -39,220 | |||
| Income tax expense | 7 | |||
| Net loss | -39,227 | |||
| Series a preferred stock conversion inducement | 18,516 | |||
| Deemed dividend related to seriesb-2 preferred stock down round provision | 11,947 | |||
| Undeclared dividends on series a preferred stock | 0 | |||
| Net loss attributable to common stockholders | -69,690 | |||
| Basic EPS | -1.84 | |||
| Diluted EPS | -1.84 | |||
| Basic Average Shares | 37,897,785 | |||
| Diluted Average Shares | 37,897,785 | |||
TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. (TLSI)